	US 11,925,608 B2
	Stabilization of epinephrine formulations
Yosyong Surakitbanharn, San Diego, CA (US)
Assigned to YS PHARMTECH, San Diego, CA (US)
Appl. No. 16/650,979
Filed by YS PHARMTECH, San Diego, CA (US)
PCT Filed Sep. 26, 2018, PCT No. PCT/US2018/052801 § 371(c)(1), (2) Date Mar. 26, 2020, PCT Pub. No. WO2019/067505, PCT Pub. Date Apr. 4, 2019.
Claims priority of provisional application 62/563,521, filed on Sep. 26, 2017.
Prior Publication US 2020/0268689 A1, Aug. 27, 2020
Int. Cl. A61K 31/137 (2006.01); A61K 47/18 (2017.01); A61K 47/20 (2006.01); A61K 47/69 (2017.01); A61M 5/24 (2006.01); A61K 9/00 (2006.01)

CPC A61K 31/137 (2013.01) [A61K 47/183 (2013.01); A61K 47/20 (2013.01); A61K 47/6951 (2017.08); A61M 5/24 (2013.01); A61K 9/0019 (2013.01)]

23 Claims

1. A pharmaceutical composition comprising:

epinephrine;

cysteine being present in the composition in an amount of about 0.05 wt. % to about 0.005 wt. % on a free base basis; and

an aqueous medium;

wherein the pharmaceutical composition has a pH of at least 3.5.